BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33569615)

  • 1. Spatiotemporal habitats from multiparametric physiologic MRI distinguish tumor progression from treatment-related change in post-treatment glioblastoma.
    Kim M; Park JE; Kim HS; Kim N; Park SY; Kim YH; Kim JH
    Eur Radiol; 2021 Aug; 31(8):6374-6383. PubMed ID: 33569615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low conductivity on electrical properties tomography demonstrates unique tumor habitats indicating progression in glioblastoma.
    Park JE; Kim HS; Kim N; Kim YH; Kim JH; Kim E; Hwang J; Katscher U
    Eur Radiol; 2021 Sep; 31(9):6655-6665. PubMed ID: 33880619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatiotemporal Heterogeneity in Multiparametric Physiologic MRI Is Associated with Patient Outcomes in IDH-Wildtype Glioblastoma.
    Park JE; Kim HS; Kim N; Park SY; Kim YH; Kim JH
    Clin Cancer Res; 2021 Jan; 27(1):237-245. PubMed ID: 33028594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor habitat analysis by magnetic resonance imaging distinguishes tumor progression from radiation necrosis in brain metastases after stereotactic radiosurgery.
    Lee DH; Park JE; Kim N; Park SY; Kim YH; Cho YH; Kim HS
    Eur Radiol; 2022 Jan; 32(1):497-507. PubMed ID: 34357451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
    Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
    Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
    Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
    Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Habitat Analysis Using Longitudinal Physiological MRI to Predict Tumor Recurrence After Stereotactic Radiosurgery for Brain Metastasis.
    Lee DH; Park JE; Kim N; Park SY; Kim YH; Cho YH; Kim JH; Kim HS
    Korean J Radiol; 2023 Mar; 24(3):235-246. PubMed ID: 36788768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypovascular Cellular Tumor in Primary Central Nervous System Lymphoma is Associated with Treatment Resistance: Tumor Habitat Analysis Using Physiologic MRI.
    Jeong SY; Park JE; Kim N; Kim HS
    AJNR Am J Neuroradiol; 2022 Jan; 43(1):40-47. PubMed ID: 34824097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Value of Vascular Permeability Estimates Using Dynamic Susceptibility Contrast MRI: Improved Diagnostic Performance in Distinguishing Hypervascular Primary CNS Lymphoma from Glioblastoma.
    Lee B; Park JE; Bjørnerud A; Kim JH; Lee JY; Kim HS
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1415-1422. PubMed ID: 30026384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric MRI as a potential surrogate endpoint for decision-making in early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a systematic review and meta-analysis.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
    Eur Radiol; 2018 Jun; 28(6):2628-2638. PubMed ID: 29374321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
    de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
    J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
    Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
    Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.
    de Godoy LL; Chawla S; Brem S; Wang S; O'Rourke DM; Nasrallah MP; Desai A; Loevner LA; Liau LM; Mohan S
    J Neurooncol; 2023 May; 163(1):173-183. PubMed ID: 37129737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy.
    Larsson C; Groote I; Vardal J; Kleppestø M; Odland A; Brandal P; Due-Tønnessen P; Holme SS; Hope TR; Meling TR; Fosse E; Emblem KE; Bjørnerud A
    Magn Reson Imaging; 2020 May; 68():106-112. PubMed ID: 32004711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glioblastoma: Vascular Habitats Detected at Preoperative Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Predict Survival.
    Juan-Albarracín J; Fuster-Garcia E; Pérez-Girbés A; Aparici-Robles F; Alberich-Bayarri Á; Revert-Ventura A; Martí-Bonmatí L; García-Gómez JM
    Radiology; 2018 Jun; 287(3):944-954. PubMed ID: 29357274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
    Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
    Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.
    Song J; Kadaba P; Kravitz A; Hormigo A; Friedman J; Belani P; Hadjipanayis C; Ellingson BM; Nael K
    Neuro Oncol; 2020 Nov; 22(11):1658-1666. PubMed ID: 32193547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparametric MRI for Differentiation of Radiation Necrosis From Recurrent Tumor in Patients With Treated Glioblastoma.
    Nael K; Bauer AH; Hormigo A; Lemole M; Germano IM; Puig J; Stea B
    AJR Am J Roentgenol; 2018 Jan; 210(1):18-23. PubMed ID: 28952810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.
    Lee JY; Bjørnerud A; Park JE; Lee BE; Kim JH; Kim HS
    Eur Radiol; 2019 Oct; 29(10):5539-5548. PubMed ID: 30877463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.